The simultaneous infusion of ATM-AVI with likely synchronous concentration profiles at the site of infection and the avoidance of a redundant beta-lactam (ceftazidime) support the use of this single-formulation product even though it has not directly been tested against ceftazidime–avibactam and ATM in clinical trials. The gene discussed is ATM; the disease is infection.